GDRX
GoodRx Holdings Inc

5,957
Mkt Cap
$947.02M
Volume
1.41M
52W High
$5.81
52W Low
$2.61
PE Ratio
32.48
GDRX Fundamentals
Price
$2.79
Prev Close
$2.79
Open
$2.79
50D MA
$3.39
Beta
1.35
Avg. Volume
2.64M
EPS (Annual)
$0.0418
P/B
1.58
Rev/Employee
$1.07M
Loading...
Loading...
News
all
press releases
Hims & Hers Plunges 29.1% in 6 Months: Time to Hold the Stock or Sell?
HIMS expands into Canada and Europe while facing regulatory hurdles and execution risks in weight-loss care.
Zacks·3d ago
News Placeholder
More News
News Placeholder
GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Rating of "Hold" by Analysts
Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) have been given an average rating of "Hold" by the thirteen analysts that are covering the stock, MarketBeat Ratings reports. One...
MarketBeat·5d ago
News Placeholder
XTX Topco Ltd Boosts Stake in GoodRx Holdings, Inc. $GDRX
XTX Topco Ltd increased its position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 281.2% during the second quarter, according to its most recent filing with the Securities...
MarketBeat·12d ago
News Placeholder
HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside?
Hims & Hers and GoodRx are reshaping virtual care, but which one leads in platform strategy and patient engagement? Let's dive in.
Zacks·14d ago
News Placeholder
LSV Asset Management Takes Position in GoodRx Holdings, Inc. $GDRX
LSV Asset Management acquired a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange...
MarketBeat·20d ago
News Placeholder
Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model
HIMS expands its connected care model with new diagnostics, hormonal health services and at-home testosterone treatments.
Zacks·21d ago
News Placeholder
GoodRx (NASDAQ:GDRX) Sets New 1-Year Low - What's Next?
GoodRx (NASDAQ:GDRX) Reaches New 12-Month Low - Here's Why...
MarketBeat·24d ago
News Placeholder
GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic and Wegovy
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced two major initiatives to make FDA-approved GLP-1 medications more widely available. First, the launch...
Business Wire·25d ago
News Placeholder
GoodRx (NASDAQ:GDRX) Downgraded by Wall Street Zen to Hold
Wall Street Zen downgraded shares of GoodRx from a "buy" rating to a "hold" rating in a report on Saturday...
MarketBeat·26d ago
News Placeholder
GoodRx Holdings, Inc. $GDRX Shares Purchased by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. boosted its position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 16.5% in the 2nd quarter, according to the company in its most recent 13F...
MarketBeat·28d ago

Latest GDRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.